Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. reports developments as a metabolic health and wellness company built around the OPTAVIA science-backed, coach-guided lifestyle system. Its updates center on revenue trends, gross margin, active earning coaches, coach productivity and the company's shift toward metabolic health amid changes in weight-loss demand and GLP-1 medication adoption.
Recurring company news also covers OPTAVIA program evidence, nutrition and habit-creation offerings, HSA/FSA reimbursement availability on select insurance plans, independent coach community initiatives, media content tied to metabolic health, and governance matters such as board nominations and stockholder cooperation agreements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Medifast (NYSE: MED) will report its financial results for Q1 2023, which ended on March 31, on May 1, 2023, after the market closes. This announcement will be followed by a conference call at 4:30 PM ET the same day, featuring Dan Chard, CEO, and Jim Maloney, CFO. The call will be accessible via the Investor Relations section of Medifast's website and archived until August 1, 2023. Medifast is a leader in the U.S. weight management industry, generating around $7 billion in revenue and known for its OPTAVIA brand that promotes healthy habits. The company has received recognition as one of America’s Best Mid-Sized Companies and has positively impacted over 2 million lives through its health and wellness community.
Summary not available.